Category: Urovant

Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Oct. 21, 2019– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced that it will be initiating part 2 of the COURAGE study, an international phase 3 trial to evaluate the safety and efficacy of vibegron for the treatment of symptoms of overactive bladder…

Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period 41% of patients on vibegron became “dry,” defined as having no urge urinary incontinence episodes at week 52 Vibegron demonstrated a favorable long-term safety and tolerability profile consistent with previous clinical experience Over 2,600 OAB patients have been treated…

Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting

Pivotal Phase 3 EMPOWUR study met both co-primary endpoints, with significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p<0.0001 and p<0.001, respectively), and a favorable safety and tolerability profile   Efficacy observed at week 2 and maintained through week 12 in co-primary endpoints Data showed once-daily 75 mg dose has…

Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

IRVINE, Calif. & BASEL, Switzerland, March 27, 2019–(BUSINESS WIRE)–Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptoms of overactive bladder (OAB) in men who are receiving pharmacological…

Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p<0.0001 and p<0.001, respectively) Vibegron met all seven key secondary endpoints, including a clinically meaningful reduction in daily urgency episodes versus placebo (p=0.002) Vibegron achieved rapid onset at two weeks in both co-primary endpoints and…

Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019

BASEL, Switzerland & IRVINE, Calif. — (BUSINESS WIRE) — Jan. 15, 2019– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New York City on Thursday, February 7, 2019. The event will feature presentations by clinical experts in the field of…